glp 1 ibd Tolerability of GLP-1 RAs in The role of GLP-1 RA

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial

"Gain muscle and lose fat!" is, of course, a way sexier sales pitch than "help your cells work more efficiently," but we were surprised at just how good this stuff really is - time and time again

Skin texture improvements from GHK-Cu typically emerge around weeks 4-6, with full collagen remodeling continuing through week 12

bariatric procedure volumes declined 11.4% in 2025 reversing a two-decade growth trend as semaglutide and tirzepatide provide comparable weight loss outcomes for class I and class II obesity without surgical risk, recovery time, or nutritional deficiency complications